Advertisement

Topics

Latest "Athera Biotechnologies" News Stories

10:52 EDT 18th July 2018 | BioPortfolio

Here are the most relevant search results for "Athera Biotechnologies" found in our extensive news archives from over 250 global news sources.

More Information about Athera Biotechnologies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Athera Biotechnologies for you to read. Along with our medical data and news we also list Athera Biotechnologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Athera Biotechnologies Companies for you to search.

Showing "Athera Biotechnologies" News Articles 1–25 of 183

Relevant

Athera Biotechnologies AB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 19022018] Prices from USD $250

SummaryAthera Biotechnologies AB Athera is a biopharmaceutical company that develops targeted anti inflammatory biological candidate drugs and companion diagnostics for cardiovascular disease. The company's product includes PCmAb, which is a fully human monoclonal antibody that neutralizes a key driver of vascular inflammation, phosphorylcholine. It has developed a proprietary companion diagnostic...


Deals this week: Refuge Biotechnologies, Attenua, Crescendo Biologics

US-based Refuge Biotechnologies Inc has raised $25m in a series B funding round led by 3SBio and Sequoia China. The...Read More... The post Deals this week: Refuge Biotechnologies, Attenua, Crescendo Biologics appeared first on Drug Development Technology.

#jobs #lifescience FUJIFILM Diosynth Biotechnologies: Principal Scientist (Analytical Development) x 2

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: FUJIFILM Diosynth Biotechnologies: Principal Scientist (Analytical Development) x 2 . Competitive: FUJIFILM Diosynth Biotechnologies: Fujifilm Diosynth Biotechnologies based in Billingham, Stockton-on-Tees specialise in developing manufacturing processes for… Billingham,...


INVITROGEN MOTHER E-BASE BY ETHROG BIOTECHNOLOGIES

$35.00End Date: Friday Aug-3-2018 5:25:47 PDTBuy It Now for only: $35.00Buy It Now | Add to watch list Biotech365 : INVITROGEN MOTHER E-BASE BY ETHROG BIOTECHNOLOGIES BioMarketplace You want to propose your products or a Biotech Company, a Biotech Tool … Continue reading → Cet article INVITROGEN MOTHER E-BASE BY ETHROG BIOTECHNOLOGIES est apparu en premier sur Biotech 365.

Elanix Biotechnologies: Erfolgreiche Finanzierungsrunde

Ende Mai hat Elanix Biotechnologies eine Kapitalerhöhung angekündigt, heute kommt die Vollzugsmeldung der Berliner. Die Gesellschaft hat fast 0,68 Millionen Aktien ausgegeben. Der Bezugspreis je Ak...

Aegea Biotechnologies' next generation nucleic acid clinical diagnostic technologies gets US, Australian & Chinese patents

Aegea Biotechnologies, a biotechnology company, announces the issuance of a collection of patents including US Patent 9,428,747 entitled methods for amplification of nucleic acids utilising hairpin loop or duplex

Arbor Biotechnologies Comes Out of Stealth Mode

Arbor Biotechnologies came out of stealth mode yesterday with a $15.6 million Series A financing round.

Azelis and Tagra Biotechnologies Extend Partnership

Israel’s Tagra Biotechnologies has appointed Azelis as the exclusive distributor of its range of Release on Demand (RND) microcapsules for all personal care applications in France and Benelux, with immediate effect. This latest agreement builds on an existing partnership between the two companies in most of Europe as well as in Canada, China, India, Australia and New Zealand.

CEO Salzman, CMO Contouriotis Resign from Adverum Biotechnologies

Amber Salzman has resigned from her position as president and CEO of Adverum Biotechnologies (NASDAQ: ADVM) effective May 3. She has also stepped down from the Menlo Park, CA, gene therapy developer’s board. Adverum said in securities filing that the resignation was a mutual decision as the board and Salzman agreed that the company is […]

Refuge Biotechnologies Raises $25 Million With Support from Chinese Investors

Chinese investment firms 3SBio and Sequoia China joined a team of other investors to bankroll California-based Refuge Biotechnologies, Inc.’s $25 million funding round to support its gene therapy treatments using CRISPR technology.

Global Aptamers Market Survey and Trend Research 2018 [Report Updated: 25012018] Prices from USD $2600

SummaryThis report describes the development of the industry by upstream downstream, industry overall and development, key companies, as well as type segment market application and so on, and makes a scientific prediction for the development industry prospects on the basis of analysis, finally, analyzes opportunities for investment in the industry at the end of the report.Industry Chain Raw M...

Elanix Biotechnologies AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Elanix Biotechnologies AG / Total Voting Rights Announcement 20.02.2018 / 13:29 Total Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of total number of voting rights 1. Details of issuer Elanix Biotechnologies AG Kurfürstendamm 32 10719 Berlin German...

Adverum Biotechnologies Announces Leadership Changes

MENLO PARK, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced that the board of directors and Amber Salzman, Ph.D., president and chief executive officer and director, made a mutual determination that Dr. Salzman step down from these roles, effec...

Adverem Biotechnologies: Gene Therapy Company And Our New Buy

Adverum Biotechnologies: Gene Therapy Company And Our New Buy

Mount Tam Biotechnologies Announces Stockholder Approvals

NOVATO, CA, May 31, 2018 (GLOBE NEWSWIRE) -- Mount Tam Biotechnologies, Inc. ("Mount Tam" or the “Company”) (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, is pleased to announce that stockholders holding a majority of the Company’s common stock voted to approve the following actions: Increase the number of authorized shares of common stoc...

AXIM Biotechnologies Reports Year End 2017 Results

­­ NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced financial results for the quarter and year ended December 31, 2017, and provided an overview of recent operational highlights. “During the year, we continued to make solid progress with our clinical pipeline of...

Mount Tam Biotechnologies Announces Appointment of New Member to the Board of Directors

NOVATO, CA, June 28, 2018 (GLOBE NEWSWIRE) -- Mount Tam Biotechnologies, Inc. ("Mount Tam" or the “Company”) (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, is pleased to announce that James Farrell has joined its Board of Directors.  James (Jim) Farrell is a successful strategist, innovator, entrepreneur and investor across a number of f...

HOVERINK BIOTECHNOLOGIES INITIATES PRIVATE PLACEMENT OF CONVERTIBLE NOTES

LOS ANGELES, CA, April 27, 2018 (GLOBE NEWSWIRE) -- Hoverink Biotechnologies, Inc announced today it intends to offer, subject to market and other conditions, $2.5 million of Series A Convertible Notes, through a Regulation D 506(b) offering to qualified buyers. The Notes would be convertible into Hoverink common stock and would have a two-year term. the Notes and the common stock issuable up...

Adverum Biotechnologies and Editas Medicine Extend Research Collaboration

MENLO PARK, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT). The companies established this collaboration to explore the delivery of genome editing ...

Adverum Biotechnologies Announces Closing of $69 Million Public Offering

MENLO PARK, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the closing of its previously announced underwritten public offering of its common stock.  Adverum Biotechnologies sold 10,222,235 shares of its common stock, including 1...

Arbor Biotechnologies Discovers New CRISPR System Utilizing its Discovery Platform

 Findings Published in the Journal Molecular Cell   $15 Million Series A Financing to Scale Biodiscovery CAMBRIDGE, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, an early stage life sciences company, today published its first findings of a new member of the CRISPR-Cas13 enzyme family—Cas13d, arising from Arbor’s discovery platform.    In its paper published today...

Adverum Biotechnologies to Present at the 2018 Jefferies Global Healthcare Conference

MENLO PARK, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that Leone Patterson, interim president and chief executive officer of Adverum, will present at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthcare ...

Adverum Biotechnologies Announces Proposed Public Offering of Common Stock

MENLO PARK, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced that it has commenced an underwritten public offering of its common stock.  The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% ...

Adverum Biotechnologies Announces Pricing of $60 Million Public Offering of Common Stock

MENLO PARK, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the pricing of an underwritten public offering of 8,888,900 shares of its common stock at a price to the public of $6.75 per share. The gross proceeds from this offering are...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks